Featured Content:
March 20, 2010
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH). In a previously conducted Phase 1B, PMX-60056 demonstrated safety and efficacy in reversing heparin in healthy subjects. PMX-60056, one of PolyMedix’s lead compounds, is designed as a small synthetic molecule to reverse heparin-induced anticoagulation…
Go to Source… Continue reading
March 20, 2010
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance. Sleep maintenance difficulty, defined as waking frequently during the night and/or waking too early and being unable to return to sleep, is the most commonly reported nighttime symptom of insomnia…
Go to Source… Continue reading
March 20, 2010
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance. Sleep maintenance difficulty, defined as waking frequently during the night and/or waking too early and being unable to return to sleep, is the most commonly reported nighttime symptom of insomnia…
Go to Source… Continue reading
March 20, 2010
The Hampton University Skin of Color Research Institute (HUSCRI) is partnering with Eastern Virginia Medical School (EVMS) to present its inaugural research symposium, “From Benchtop to Bedside,” Friday, April 30-Sunday, May 2, 2010, at the Colonial Williamsburg Lodge and Conference Center…
Go to Source… Continue reading
March 20, 2010
GE Healthcare, the $17 billion medical technology division of General Electric Company (NYSE:GE), today announced the Mac-Lab’s validation of compatibility with the Volcano’s SmartMap® Pressure Instrument and PrimeWire® Pressure Guide Wire for evaluation of Fractional Flow Reserve (FFR). Coronary heart disease caused 425,425 deaths in 2006 and is the single leading cause of death in America today1. It is caused by atherosclerosis, the narrowing of the coronary arteries due to fatty build ups of plaque. It’s likely to produce angina pectoris (chest pain), heart attack or both…
Go to Source… Continue reading
March 20, 2010
Hugs, high fives, cheers and a few tears will abound when the Johns Hopkins University School of Medicine’s seniors find out which hospital residency programs they will enter after graduation this spring. The fourth-year students will gather for this annual, invitation-only celebration on the medical campus, where they’ll open official letters in the presence of classmates, professors and loved ones. The event for the 107th graduating class is slated to take place on Thursday, March 18, from 10:30 a.m. to 12 p.m…
Go to Source… Continue reading
March 20, 2010
Listed below are story ideas from the Johns Hopkins University School of Medicine with a partial focus on the upcoming NCAA basketball tournaments. NCAA Basketabll Tournament Coaches, Referees, Players And Fans: It’s Your Voice! From the first tip-off of March Madness to the championship’s final buzzer, thousands of people will relentlessly scream and shout, placing tremendous strain on the voice. While no one is recommending silence, the constant pressure on the vocal chords can cause great damage…
Go to Source… Continue reading
March 20, 2010
Authors: Kim WC, Lee CH
Ribonucleases (RNases) are a group of enzymes that cleave RNAs at phosphodiester bonds resulting in remarkably diverse biological consequences. This review focuses on mammalian RNases that are capable of, or potentially capable of, cleaving messenger RNA (mRNA) as well as other RNAs in cells and play roles in the development of human cancers. The aims of this review are to provide an overview of the roles of currently known mammalian RNases, and the evidence that associate them as regulators of tumor development. The roles of these RNases as oncoproteins and/or tumor suppressors in influencing cell… Continue reading
